Spleen Volume Linked to Outcome After HSCT for Leukemia Patients
WEDNESDAY, July 19, 2023 -- For patients with acute myeloid leukemia (AML), higher spleen volume at the time of hematopoietic stem cell transplant (HSCT) is associated with inferior overall survival and an increased incidence of nonrelapse mortality... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 19, 2023 Category: Pharmaceuticals Source Type: news
Aptevo Therapeutics Stock Is Sinking Today - Here's Why
Aptevo Therapeutics Inc APVO announced that its bispecific acute myelogenous leukemia (AML) drug candidate APVO436, in combination with venetoclax and azacitidine, achieved positive duration of remission results in its Phase 1b dose-escalation trial. High response rate observed: 82% (9/11) of…#aml #durationofremission #dor #phase2 #1h24 #apvo (Source: Reuters: Health)
Source: Reuters: Health - July 18, 2023 Category: Consumer Health News Source Type: news
Why Wall Street shaved a third of Peninsula cancer cell therapy company's value despite good news
Four of six acute myeloid leukemia patients had "complete responses" to the company's "natural killer" cell therapy in combination with two chemotherapy drugs. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 27, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Schoolgirl with rare cancer given 'no hope' is now in remission after transplant from baby
Eight-year-old Sarah Marica, a little warrior battling acute myeloid leukaemia , was deemed beyond saving until a groundbreaking stem cell transplant from a newborn baby's umbilical cord changed her fate. (Source: Daily Express - Health)
Source: Daily Express - Health - June 22, 2023 Category: Consumer Health News Source Type: news
Gilteritinib Maintenance Reduces Relapse in MRD+ AML Gilteritinib Maintenance Reduces Relapse in MRD+ AML
Patients with acute myeloid leukemia and who have minimal residual disease following hematopoietic cell transplantation have a reduced risk of relapse with gilteritinib maintenance therapy.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Allogeneic Hematopoietic Cell Transplant Outcomes Improved From 2005 to 2019
FRIDAY, June 16, 2023 -- Outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with acute myeloid leukemia (AML) and second complete remission (CR2) have significantly improved over time, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 16, 2023 Category: Pharmaceuticals Source Type: news
The Petri Dish: 2seventy bio pauses trial after patient death; Biogen begins a contentious board shakeup
2seventy bio, the cancer-focused spinout of bluebird bio, has paused a clinical trial in acute myeloid leukemia after a child died at Seattle Children's. Plus, other life sciences news you may have missed. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 15, 2023 Category: American Health Authors: Rowan Walrath Source Type: news
Adding Mylotarg to Chemo Fails to Boost Survival in NPM1-Mutated AML
(MedPage Today) -- There was bad news and good news in a phase III trial evaluating intensive chemotherapy with or without gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia (AML) patients with newly diagnosed, NPM1-mutated disease.
For... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 15, 2023 Category: Hematology Source Type: news
FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia
(MedPage Today) -- Incorporating quizartinib into standard treatment for newly diagnosed acute myeloid leukemia (AML) followed by maintenance therapy with the investigational FLT3 inhibitor improved survival for patients with internal-tandem-duplication... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 10, 2023 Category: Hematology Source Type: news
Berkshire woman raises awareness of acute myeloid leukaemia
Mary Forester says in retrospect there were some red flags but they were all easily explained away. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 16, 2023 Category: Consumer Health News Source Type: news
Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies | Science Signaling
Inhibiting the ROS-generating Rac-NOX2 complex delays the progression of FLT3 mutant acute myeloid leukemia. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - March 28, 2023 Category: Science Source Type: news
Processed Red Meat Intake Linked to Increased Incidence of Blood Cancers
FRIDAY, March 24, 2023 -- Processed red meat intake is associated with an increased incidence of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in a Japanese population, according to a study published online March 7 in Environmental... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2023 Category: Pharmaceuticals Source Type: news
Variants ID Outcomes in Adults With Leukemia in Relapse Prior to Stem Cell Transplant
TUESDAY, March 21, 2023 -- For patients with acute myeloid leukemia (AML) in first remission prior to allogeneic hematopoietic cell transplant, specific variants can identify patients at risk for increased relapse and worse survival, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 21, 2023 Category: Pharmaceuticals Source Type: news
Blood test identifies acute myeloid leukemia patients at greater risk for relapse after bone marrow transplant
A small portion of adults in remission from a deadly blood cancer had persisting mutations that were detected, which predicted their risk of death from having the cancer return. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - March 7, 2023 Category: American Health Source Type: news
Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer
Recent advances in cancer genomics have deepened the medical community ’s understanding of the molecular alterations in braintumours, more preciselysubclassifying patients into specific diagnoses.Understanding a patient ' sbraintumour mutation status in the IDH1 and ATRX genes enables more informed clinical decisions and may improve patient outcomes.The IDH1 R132H and ATRX antibodies are the latest additions to Roche ’s neuropathology portfolio, which contains 29 biomarkers.Basel, 23 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibo...
Source: Roche Media News - February 23, 2023 Category: Pharmaceuticals Source Type: news
